Insilico Medicine announced the selection of ISM5059, a peripheral‑restricted NLRP3 inhibitor discovered using generative AI platforms, as its lead preclinical candidate. The company reported that ISM5059 was optimized for target engagement and peripheral exposure to limit central nervous system penetration—an important safety design feature for chronic inflammatory indications. The nomination underscores the increasing role of AI in small‑molecule design and candidate nomination. Insilico said it will advance ISM5059 through IND‑enabling studies with the intention of filing for human trials; the program will test whether AI‑accelerated chemistry can shorten discovery timelines while meeting standard preclinical benchmarks.